Broad spectrum, robust pathogen reduction
The INTERCEPT Blood System for Platelets, pathogen reduction system, provides robust, broad spectrum reduction, reducing the risks of TTI, including sepsis.1 In addition, the number of T-cells is reduced to a level that potentially reduces the risk of transfusion-associated graft-versus-host disease (TA-GVHD).1
 |
Bacteria (gram-negative, gram-positive, spirochetes) |
Log Reduction1 (cfu/mL)a,b | |
| Platelets in 65% PAS-3/ 35% plasma |
Platelets in 100% Plasma |
||
| Klebsiella pneumoniae | 5.8 | 5.9 | |
| Escherichia coli | ≥6.3 | >5.9 | |
| Serratia marcescens | ≥6.7c | >7.1 | |
| Pseudomonas aeruginosa | ≥3.9 | ≥6.8 | |
| Salmonella choleriaesuis | 6.2 | >5.9 | |
| Enterobacter cloacae | 5.5 | ≥6.0 | |
| Yersenia enterocolitica | ≥5.9 | >6.3 | |
| Staphylococcus epidermidis | ≥6.1 | >6.1 | |
| Staphylococcus aureus | ≥5.4 | ≥6.1 | |
| Listeria monocytogenes | ≥6.3c | >6.6 | |
| Corynebacterium minutissimum | ≥5.3 | >6.4 | |
| Streptococcus pyogenes | ≥6.8c | >6.1 | |
| Bacillus cereus (vegetative) | ≥5.5 | ≥5.6 | |
| Bacillus cereus (spore forming) | 3.7c | d | |
| Bifidobacterium adolescentis | ≥6.0 | d | |
| Clostridium perfringens (vegetative) | ≥6.5 | >6.0 | |
| Propionibacterium acnes | ≥6.5 | >6.7 | |
| Treponema pallidum (Syphilis) | ≥6.4 | b | |
| Borrelia burgdorferi (Lyme disease) | ≥6.8 | b | |
 |
Virus (enveloped and non-enveloped) |
Log Reduction1 (pfu/mL)a | |
| Platelets in 65% PAS-3/ 35% plasma |
Platelets in 100% Plasma |
||
| HIV-1 IIIB, cell-associated | ≥5.4 | ≥4.7 | |
| HIV-1 IIIB, cell-free | ≥5.6 | d | |
| HIV-1 Z84 (clinical isolate) | ≥3.3 | d | |
| HIV-2 CLB-20 (clinical isolate) | ≥2.4 | d | |
| DHBV (model virus for HBV) | ≥4.8 | ≥4.3 | |
| BVDV (model virus for HCV) | ≥4.4 | >3.3 | |
| HTLV-I | 4.7 | d | |
| HTLV-II | ≥5.1 | d | |
| West Nile virus (WNV) | ≥5.7 | >3.7 | |
| Chikungunya virus (CHIKV) | ≥5.7 | >6.5 | |
| Dengue virus (DENV) | ≥4.3 | 3.6 | |
| Cytomegalovirus (CMV) | ≥4.9 | d | |
| Pseudorabies Virus (model for CMV) | d | ≥4.2 | |
| Influenza A virus | ≥5.9 | d | |
| Calcivirus (model non-enveloped virus) | 2.1 | 0.9 | |
| Adenovirus | ≥4.9 | ≥5.3 | |
| Bluetongue virus (model non-enveloped virus) | 4.4 | d | |
 |
Protozoan Parasite | Log Reduction1 (pfu or cfu/mL)a | |
| Platelets in 65% PAS-3/ 35% plasma |
Platelets in 100% Plasma |
||
| Plasmodium falciparum | ≥5.6 | b | |
| Babesia microti | ≥4.9 | b | |
| Trypanosoma cruzi | ≥5.3 | >5.5 | |
| Leishmania mexicana (metacyclic promastigote stage) |
≥5.0 | d | |
| |
|
||
 |
Leukocyte | Log Reduction1 | |
| Platelets in 65% PAS-3/ 35% plasma |
Platelets in 100% Plasma |
||
| Human T-Cells | 4.0 | 4.0 | |
For a full list of pathogens, see Package Insert.
a. Based on input titer and post-treatment titer in 1 mL, data obtained in platelet components in PAS-3 or plasma compnents
b. Study in progress
c. Based on culture of full platelet unit (300mL).
d. Not tested
References
- The INTERCEPT Blood System for Platelets- Dual Storage Set Package Insert, March 15, 2016